8.1 Inotropes, Vasopressors & Inodilators

Adrenergic and Non-Adrenergic Receptor Physiology

Inotropic, vasopressor, and inodilator therapies represent essential pharmacologic interventions in the Cardiac Intensive Care Unit (CICU) for restoring organ perfusion, augmenting cardiac output, and normalizing systemic vascular resistance. Safe and effective clinical titration requires a thorough understanding of signal transduction pathways, receptor distribution, and cellular responses across the cardiovascular system.

Vascular and Cardiac Adrenergic Receptor Cascades

• Alpha-1 (α₁) Adrenergic Receptors: Located predominantly on vascular smooth muscle of peripheral resistance arterioles and venous capacitance vessels. α₁ receptors couple to the Gq protein subunit, activating phospholipase C (PLC). PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP₂) into inositol trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ triggers calcium release from the sarcoplasmic reticulum, raising intracellular free calcium ([Ca²⁺]i) and stimulating vascular smooth muscle contraction. This results in arterial vasoconstriction, elevated Systemic Vascular Resistance (SVR), increased Pulmonary Vascular Resistance (PVR), elevated Mean Arterial Pressure (MAP), and enhanced venous return (preload).
• Beta-1 (beta₁) Adrenergic Receptors: Concentrated in cardiac tissue, including the sinuatrial (SA) node, atrioventricular (AV) node, and atrial/ventricular cardiomyocytes. beta₁ receptors couple to the Gₛ protein subunit, activating adenylyl cyclase to convert adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). Rising cAMP levels activate Protein Kinase A (PKA), which phosphorylates L-type calcium channels, ryanodine receptors, and phospholamban. The clinical result encompasses positive inotropy (contractility), positive chronotropy (heart rate), positive dromotropy (AV conduction velocity), and positive bathmotropy (excitability), leading to increased Cardiac Output (CO), Stroke Volume (SV), and Myocardial Oxygen Demand (MVO₂).
• Beta-2 (beta₂) Adrenergic Receptors: Located on vascular smooth muscle supplying skeletal muscle, coronary circulation, splanchnic beds, and bronchial smooth muscle. Coupled to Gₛ proteins, beta₂ stimulation elevates intracellular cAMP in smooth muscle cells, triggering PKA-mediated phosphorylation of myosin light-chain kinase (MLCK). Deactivation of MLCK promotes vascular and bronchial smooth muscle relaxation, yielding systemic and coronary vasodilation (decreased SVR) and bronchodilation.
• Vasopressin (V₁ₐ) Receptors: Non-adrenergic receptors expressed on vascular smooth muscle cells. V₁ₐ engagement operates through Gq-protein phospholipase C signaling, mobilizing intracellular calcium to produce profound vasoconstriction. V₁ₐ signaling remains fully active during severe lactic acidosis and hypoxia, states in which adrenergic receptors undergo desensitization and uncoupling.
• Dopaminergic (DA₁) Receptors: Located in renal, mesenteric, coronary, and cerebral vascular beds. Coupled to Gₛ proteins, DA₁ activation stimulates adenylyl cyclase to raise cAMP, causing vascular smooth muscle relaxation and selective renal and splanchnic vasodilation at low infusion concentrations.

Receptor Target Matrix for Vasoactive Support

Clinical Pharmacology of Inotropes, Vasopressors & Inodilators

1. Norepinephrine (Levophed)

• Mechanism of Action: Direct-acting sympathomimetic amine with potent α₁-adrenergic receptor agonist activity combined with modest beta₁-adrenergic agonist activity (α₁ gg beta₁).
• Clinical Indications: First-line vasopressor for septic shock, distributive shock, and cardiogenic shock presenting with severe hypotension (MAP <65 mmHg) and low SVR.
• Hemodynamic Profile: Produces intense arterial vasoconstriction, significantly increasing MAP, SVR, and systolic/diastolic blood pressure. The modest beta₁ stimulation increases stroke volume and myocardial contractility; however, reflex vagal bradycardia secondary to baroreceptor activation typically neutralizes direct beta₁ chronotropic effects, keeping heart rate relatively stable.
• Dosing & Titration: Continuous IV infusion initiated at 0.01 to 0.05 mcg/kg/min (or 2 to 5 mcg/min) and titrated rapidly every 2–5 minutes to achieve target MAP ≥ 65 mmHg. Maximum standard titration ranges up to 3.0 mcg/kg/min (roughly 210 mcg/min in a 70 kg adult); many institutional protocols cap the weight-based rate far lower, around 0.5–1.0 mcg/kg/min (35–70 mcg/min), before adding a second agent.
• Critical Nursing Considerations: Peripheral extravasation causes ischemic tissue necrosis. Acidosis (pH < 7.20) blunt receptor sensitivity, requiring higher infusion rates. Abrupt cessation can trigger profound rebound hypotension.

2. Epinephrine (Adrenalin)

• Mechanism of Action: Potent, non-selective agonist at α₁, α₂, beta₁, and beta₂ adrenergic receptors.
• Titration Dynamics & Receptor Selectivity:
  • Low Dose (0.01 to 0.05 mcg/kg/min): beta₁ and beta₂ adrenergic effects predominate. Produces robust positive inotropy, chronotropy, and enhanced cardiac output. SVR may remain unchanged or drop slightly due to beta₂-mediated vasodilation.
  • High Dose (>0.1 mcg/kg/min): α₁ adrenergic receptor stimulation overcomes beta₂ vasodilation, resulting in marked systemic arterial vasoconstriction, elevated SVR, and steep rises in MAP.
• Clinical Indications: Severe cardiogenic shock refractory to dobutamine/norepinephrine, low cardiac output syndrome post-cardiac surgery, anaphylactic shock, and cardiac arrest resuscitation (1 mg IV push every 3–5 minutes).
• Metabolic Effects & Adverse Profile: Stimulates skeletal muscle beta₂ receptors, activating Na+/K+ ATPase pumps and accelerating aerobic glycolysis to produce Type B hyperlactatemia (elevated serum lactate independent of tissue hypoperfusion). Induces severe hyperglycemia and carries high arrhythmogenicity (sinus tachycardia, atrial fibrillation, PVCs, ventricular tachycardia).

3. Dopamine

• Mechanism of Action: Immediate metabolic precursor to norepinephrine. Displays a unique, tri-phasic dose-dependent receptor engagement spectrum.
• Dose-Dependent Receptor Ranges:
  • Low Dose (0.5 to 3.0 mcg/kg/min): Stimulates vascular DA₁ receptors, dilating renal, splanchnic, coronary, and cerebral vascular beds. Clinical Pearl: AACN and KDIGO guidelines explicitly state that routine low-dose dopamine ("renal dose") is ineffective for preventing or treating acute kidney injury and should NOT be used.
  • Medium Dose (3.0 to 10.0 mcg/kg/min): Stimulates myocardial beta₁ receptors directly and promotes localized release of endogenous norepinephrine from cardiac sympathetic nerve terminals, boosting contractility, stroke volume, and cardiac output.
  • High Dose (10.0 to 20.0 mcg/kg/min): Overwhelmingly stimulates peripheral α₁ receptors, producing severe vasoconstriction and marked SVR elevation.
• Limitations & Safety Warnings: Dopamine triggers significantly more tachyarrhythmias (atrial fibrillation, VT) and is associated with higher 28-day mortality in cardiogenic shock compared to norepinephrine (SOAP II trial).

4. Dobutamine

• Mechanism of Action: Synthetic catecholamine operating as a potent, direct beta₁-adrenergic agonist with mild beta₂-adrenergic vasodilation and weak α₁ activity (beta₁ > beta₂ > α₁).
• Clinical Indications: Primary inotrope choice for acute decompensated heart failure (ADHF) and cardiogenic shock with low cardiac index (CI < 2.0 L/min/m²) and elevated filling pressures (PCWP >18 mmHg) when systolic blood pressure is adequate (SBP > 90 mmHg).
• Hemodynamic Profile: Increases stroke volume, cardiac index, and myocardial oxygen delivery while decreasing SVR, PVR, LVEDP, and PCWP. Reduces ventricular afterload, promoting forward ejection.
• Dosing & Titration: IV infusion titrated from 2.5 to 20.0 mcg/kg/min.
• Adverse Effects: Elevates MVO₂, causing myocardial ischemia in CAD. Induces tachyarrhythmias and can precipitate severe hypotension in hypovolemic patients.

5. Milrinone (Primacor)

• Mechanism of Action: Selective Phosphodiesterase-3 (PDE-3) inhibitor. Prevents degradation of intracellular cAMP in cardiac myocytes and vascular smooth muscle cells.
• Inodilator Properties: Elevates cAMP levels to enhance calcium influx during systole (positive inotropy) and accelerate calcium reuptake during diastole (positive lusitropy). In vascular smooth muscle, elevated cAMP causes potent systemic and pulmonary arterial vasodilation and venodilation (afterload and preload reduction).
• Adrenergic Receptor Independence: Acts downstream of adrenergic receptors; remains fully effective in patients receiving chronic beta-blocker therapy (e.g., carvedilol, metoprolol).
• Pharmacokinetics & Renal Elimination: Elimination half-life is 2.5 hours in normal renal function, extending to 4.0 to 6.0 hours in renal impairment. Excreted 85--90% unchanged by the kidneys. Mandatory dose reductions required for Creatinine Clearance (CrCl < 50 mL/min).
• Dosing: Continuous IV infusion at 0.125 to 0.75 mcg/kg/min. Loading doses (50 mcg/kg over 10 min) are routinely omitted in CICU settings to prevent acute, severe hypotension.

6. Vasopressin (Argipressin / ADH)

• Mechanism of Action: Direct non-adrenergic agonist at vascular V₁ₐ receptors. Activates Gq-PLC signaling to raise intracellular calcium in vascular smooth muscle cells.
• Clinical Role: Second-line non-adrenergic vasopressor added to norepinephrine in septic shock (0.03 units/min fixed dose) or vasoplegic syndrome post-cardiopulmonary bypass (0.01 to 0.04 units/min).
• Hemodynamic Advantages: Restores arterial tone in severe acidosis without causing tachyarrhythmias. Selectively constricts efferent renal arterioles, maintaining glomerular filtration rate (GFR) and urine output.

7. Extravasation Management & Nursing Interventions

• Pathophysiology: Peripheral IV extravasation of α₁ vasopressors (norepinephrine, epinephrine, dopamine, phenylephrine) causes intense localized vasoconstriction, severe tissue ischemia, blanched cool skin, blistering, induration, and ischemic necrosis/sloughing.
• AACN Nursing Extravasation Protocol:
  1. Immediately stop the vasoactive infusion.
  2. Do NOT remove the IV catheter immediately; attach a syringe and aspirate as much extravasated drug as possible from the cannula before removal.
  3. Administer Phentolamine (Regitine): A competitive non-selective α₁-adrenergic receptor antagonist. Dilute 5 to 10 mg of phentolamine in 10 to 15 mL of 0.9% sodium chloride. Using a fine-gauge (25–27G) needle, infiltrate small quantities subcutaneously in a circular pattern throughout the blanched, ischemic area within 12 hours of extravasation.
  4. Elevate the extremity and apply warm compresses to promote localized blood flow.
  5. Ensure all continuous vasoactive infusions are administered via dedicated central venous catheter (CVC) lumens with real-time continuous invasive arterial blood pressure monitoring.